From Coin to Company (C2C): Building Biotech in the Internet Capital Era

Biotech doesn’t struggle because there’s a shortage of ideas. It struggles because good ideas get trapped in the wrong funding model.

The most interesting scientific work rarely starts with a billion-dollar investor. It starts with a few researchers who see something promising and can’t wait to test it, until they realize they need half a million dollars in grant approvals, 18 months of paperwork, and a network of connections they don’t have. By the time the system says “yes,” the energy that made the idea exciting is already gone.

At Curetopia, we’ve stopped waiting for that approval. We’re building science directly with internet capital, where communities fund the experiments they believe in and help form companies around real data.

This model is called Coin to Company (C2C). It’s simple:
A group with a shared mission launches a token, raises capital transparently, funds experiments in the open, and when the science works, spins it into a real company. The community becomes the first investor, the data becomes the foundation, and the process stays public from day one.

‍

The Problem With Traditional Biotech Funding

In traditional biotech, a new research idea travels through a slow, narrow pipeline:
grant → data → publication → investor interest → startup.

Each step filters out projects that don’t fit institutional priorities. The process favors prestige, not potential. Rare diseases, longevity research, and unconventional biology rarely make it through.

Even when a project succeeds, the people who believed in it earliest, the patient communities, the scientists, the small contributors, rarely own a piece of the outcome. The value pools at the top, while the curiosity and risk sit at the bottom.

This is about structure. Biotech evolved in an era before global coordination was possible. The internet changes that.

Internet Capital and the Acceleration of Science

Web3 gave us something new: internet capital markets, open, liquid, programmable systems that anyone can use to fund ideas.

We’ve seen this model create culture: memes, art, digital identity. Now it’s starting to fund science. A group that cares about longevity, neuroregeneration, or rare disease can raise capital directly, on-chain, from people who share that belief.

That capital doesn’t have to wait for approval cycles. It moves at the speed of the internet. The community can fund an experiment, watch progress live, and adjust funding or priorities in the open.

It’s science as a living, collaborative process.

‍

From Token to Data to Company

Here’s how the C2C model works in practice:

1. Formation:
   A community organizes around a question, a disease, a discovery, a hypothesis. They launch a token to represent shared belief and pooled capital.
   
   
2. Execution:
   The treasury funds real lab work, experiments designed and executed by scientists in full public view. Updates are posted live, data shared openly, and milestones verified on-chain.
   
   
3. Proof:
   When the data shows promise, that experiment becomes the foundation for a spin-out company. The early supporters become the initial cap table. The science moves from open experiment to structured development.
   
   

This is how Raptor began: a small community of researchers and builders funding real lifespan studies in C. elegans worms. Within weeks, we had experiments running. The data is now being used to inform mouse studies and IP filings, the beginnings of a proper biotech, born from open internet capital.

‍

Why This Works

When communities fund science, they bring more than money. They bring belief, accountability, and a shared sense of ownership.

Transparency makes trust native. Every update, delay, and breakthrough is visible. The scientists are reporting to a community that’s deeply invested in the outcome.

That transparency compounds credibility. It turns the research process itself into a public good. It also reduces waste: instead of overlapping grants and duplicated studies, projects coordinate openly and share what works.

And because the company formation happens after data is generated, the risk is distributed earlier and the upside is shared more fairly.

The model rebalances power. Instead of a small group of investors deciding which science gets built, communities decide. Instead of waiting for validation, they create it.

‍

What Comes Next

The next decade of biotech won’t be built in the shadows. It will be built in the open, with communities funding the science they care about and sharing in its progress.

We’re already seeing this take shape. At Curetopia, patient communities are forming research tokens for diseases that have been ignored for years. At Raptor, aging research is moving faster because the entire process, from hypothesis to experiment, happens transparently.

The bridge between crypto and biotech isn’t theoretical anymore. It’s operating. The capital is liquid. The infrastructure is live. The model works.

What’s next is scale, hundreds of small scientific networks launching, funding, and forming companies as it happens.

That’s how we build biotech for the internet capital era.
From coin, to company, to cure.

‍